BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
BioCentury | Jan 25, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million on Jan. 23 in a series B round on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor,...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
BioCentury | Jan 23, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million in a series B round Wednesday on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor, ATN-249, to...
BioCentury | Dec 7, 2018
Tools & Techniques

Filaments line up as MS biomarker

Neurofilament assays appear on track to become the biomarker of choice for a wide range of neurodegeneration studies, given their tight correlation with axon damage and detectability in blood. If prospective trials can reinforce the...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BioCentury | Apr 13, 2018
Clinical News

Wilson reports 72-week data Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 20 evaluable patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound...
BioCentury | Apr 13, 2018
Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's April 10 close of SEK136.20,...
BioCentury | Apr 11, 2018
Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's Tuesday close of SEK136.20, before...
BioCentury | Apr 10, 2018
Tools & Techniques

New framework advocates biomarker-based definition of AD

NIH's National Institute on Aging and the non-profit Alzheimer’s Association released a new framework recommending that Alzheimer's disease research define the disease based on biomarkers rather than solely using clinical symptoms. The two organizations formed...
Items per page:
1 - 10 of 38